Fate Therapeutics
Clinical-stage biopharmaceutical company pioneering the development of off-the-shelf, iPSC-derived cellular immunotherapies for cancer and immune disorders.
Notes
Fate Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California, pioneering the development of off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). The company's approach addresses key limitations of current autologous cell therapies by creating standardized, mass-produced cell products.
Fate's iPSC-derived cell therapies include natural killer (NK) cells and T cells that can be manufactured at scale and stored for on-demand use, potentially offering faster access, lower costs, and more consistent product quality compared to patient-derived cell therapies. The company has multiple clinical programs in oncology and is developing next-generation cell products with enhanced functionality.
Fate Therapeutics is publicly traded on NASDAQ under the ticker FATE.
Team
- Scott Wolchko - President & CEO
- Dan Shoemaker, Ph.D. - Chief Scientific Officer
- Edward Scheffer - Chief Operating Officer
Additional Research Findings
- Founded in 2007
- Publicly traded: NASDAQ (FATE)
- Portfolio company of Polaris Partners
- Headquarters: San Diego, California
- Pioneer in iPSC-derived cell therapy
- Off-the-shelf cellular immunotherapies
- iPSC-derived NK and T cell products
- Multiple clinical programs in oncology
- Partnership with Johnson & Johnson
- Focus on overcoming limitations of autologous cell therapy
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |